应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
01177 中国生物制药
未开盘 05-02 16:08:16
2.880
+0.180
+6.67%
最高
2.880
最低
2.720
成交量
4,532万
今开
2.720
昨收
2.700
日振幅
5.93%
总市值
541.48亿
流通市值
541.48亿
总股本
188.01亿
成交额
1.27亿
换手率
0.24%
流通股本
188.01亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
中国生物制药05月02日主力资金流入494万元 连续3日加仓
自选股智能写手 · 05-02 16:15
中国生物制药05月02日主力资金流入494万元 连续3日加仓
中国生物制药盘中异动 早盘股价大涨5.18%
自选股智能写手 · 05-02 10:51
中国生物制药盘中异动 早盘股价大涨5.18%
中国生物制药(01177)出现大手买入110万股,成交价$2.82,涉资310.2万
阿斯达克财经 · 05-02 10:50
中国生物制药(01177)出现大手买入110万股,成交价$2.82,涉资310.2万
中国生物制药:正大天晴药业安奈克替尼获批 上市81.08%客观缓解率
和讯网 · 04-30 19:22
中国生物制药:正大天晴药业安奈克替尼获批 上市81.08%客观缓解率
【港股通】中国生物制药(01177):1类创新药富马酸安奈克替尼胶囊获批上市
金吾财讯 · 04-30 16:47
【港股通】中国生物制药(01177):1类创新药富马酸安奈克替尼胶囊获批上市
中国生物制药(01177.HK)一款自主研究新药获批上市
阿斯达克财经 · 04-30 16:40
中国生物制药(01177.HK)一款自主研究新药获批上市
中国生物制药(01177)自主研发的1类创新药富马酸安奈克替尼胶囊获批上市
智通财经 · 04-30 16:35
中国生物制药(01177)自主研发的1类创新药富马酸安奈克替尼胶囊获批上市
中国生物制药04月30日获主力加仓1955万元 环比增加649.04%
自选股智能写手 · 04-30 16:15
中国生物制药04月30日获主力加仓1955万元 环比增加649.04%
港股概念追踪 |ASCO研究标题发布 机构关注国产创新药产业机会(附概念股)
智通财经 · 04-30 14:00
港股概念追踪 |ASCO研究标题发布 机构关注国产创新药产业机会(附概念股)
中国生物制药(01177):52项研究成果将在2024年ASCO年会公布
智通财经 · 04-29
中国生物制药(01177):52项研究成果将在2024年ASCO年会公布
中国生物制药:以创新填补临床空白
经济参考网 · 04-29
中国生物制药:以创新填补临床空白
中国生物制药(01177.HK)创新药TQA3038完成I期临床研究
阿斯达克财经 · 04-26
中国生物制药(01177.HK)创新药TQA3038完成I期临床研究
中国生物制药(01177):1类创新药“TQA3038 (siRNA)”完成I期临床研究
智通财经 · 04-25
中国生物制药(01177):1类创新药“TQA3038 (siRNA)”完成I期临床研究
中国生物制药04月25日遭主力抛售1512万元 环比增加987.77%
自选股智能写手 · 04-25
中国生物制药04月25日遭主力抛售1512万元 环比增加987.77%
中国生物制药(01177)出现大手卖出82.5万股,成交价$2.79,涉资230.175万
阿斯达克财经 · 04-25
中国生物制药(01177)出现大手卖出82.5万股,成交价$2.79,涉资230.175万
中国生物制药(01177)出现大手买入140万股,成交价$2.66,涉资372.4万
阿斯达克财经 · 04-24
中国生物制药(01177)出现大手买入140万股,成交价$2.66,涉资372.4万
中国生物制药(01177.HK)获主席谢其润增持200万股
港股那点事 · 04-24
中国生物制药(01177.HK)获主席谢其润增持200万股
中国生物制药(01177)出现大手买入180万股,成交价$2.59,涉资466.2万
阿斯达克财经 · 04-23
中国生物制药(01177)出现大手买入180万股,成交价$2.59,涉资466.2万
中国生物制药(01177.HK)获执行董事谢承润增持500万股
格隆汇资讯 · 04-23
中国生物制药(01177.HK)获执行董事谢承润增持500万股
大涨近9% 中国生物制药大股东增持
证券时报网 · 04-22
大涨近9% 中国生物制药大股东增持
公司概况
公司名称:
中国生物制药
所属市场:
SEHK
上市日期:
--
主营业务:
中国生物制药有限公司是一家主要从事药品业务的投资控股公司。该公司通过三个业务分部进行运营。中药现代制剂及西药分部从事生产、销售及配销中药现代制剂产品及西药产品业务。投资分部从事长期及短期投资业务。其他分部主要从事研发活动、向第三方提供服务以及从事相关医疗及医院业务。该公司还通过其子公司从事持有物业、销售健康食品、验光配镜以及零售与批发视光和听力产品业务。
发行价格:
--
{"stockData":{"symbol":"01177","market":"HK","secType":"STK","nameCN":"中国生物制药","latestPrice":2.88,"timestamp":1714637296028,"preClose":2.7,"halted":0,"volume":45315565,"delay":0,"floatShares":18801217230,"shares":18801217230,"eps":0.13646713,"marketStatus":"未开盘","marketStatusCode":0,"change":0.18,"latestTime":"05-02 16:08:16","open":2.72,"high":2.88,"low":2.72,"amount":127401369,"amplitude":0.059259,"askPrice":2.88,"askSize":1515000,"bidPrice":2.87,"bidSize":245000,"shortable":3,"etf":0,"ttmEps":0.13646713213297695,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1714699800000},"adr":0,"adjPreClose":2.7,"dividendRate":0.017099,"openAndCloseTimeList":[[1714613400000,1714622400000],[1714626000000,1714636800000]],"volumeRatio":0.6389137760365018,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"SBO.HK"},"requestUrl":"/m/hq/s/01177/wiki","defaultTab":"wiki","newsList":[{"id":"2432623752","title":"中国生物制药05月02日主力资金流入494万元 连续3日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2432623752","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2432623752?lang=zh_cn&edition=full","pubTime":"2024-05-02 16:15","pubTimestamp":1714637731,"startTime":"0","endTime":"0","summary":"05月02日, 中国生物制药股价涨6.67%,报收2.88元,成交金额1.27亿元,换手率0.24%,振幅5.93%,量比0.64。中国生物制药今日主力资金净流入494万元,连续3日净流入,上一交易日主力净流入1955万元,今日环比减少74.73%。近一年数据显示,该股主力连续3日净流入后,次日上涨概率为27.78%,平均涨幅为2.23%。该股近5个交易日上涨7.46%,主力资金累计净流入643万元,其中1个交易日为股价下跌时净流入;近20日主力资金累计净流出5271万元,其中净流出天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405021615408b6c5f2c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405021615408b6c5f2c&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2432974336","title":"中国生物制药盘中异动 早盘股价大涨5.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2432974336","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2432974336?lang=zh_cn&edition=full","pubTime":"2024-05-02 10:51","pubTimestamp":1714618284,"startTime":"0","endTime":"0","summary":"2024年05月02日早盘10时51分,中国生物制药股票出现波动,股价急速拉升5.18%。截至发稿,该股报2.841港元/股,成交量2206.85万股,换手率0.12%,振幅4.44%。中国生物制药股票所在的药品行业中,整体涨幅为0.26%。其相关个股中,君圣泰医药-B、培力农本方、翰森制药涨幅较大,振幅较大的相关个股有君圣泰医药-B、康龙化成、翰森制药,振幅分别为12.96%、8.03%、7.01%。中国生物制药公司简介:中国生物制药有限公司是一间主要从事药品业务的投资控股公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050210512587e85479&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050210512587e85479&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2432692499","title":"中国生物制药(01177)出现大手买入110万股,成交价$2.82,涉资310.2万","url":"https://stock-news.laohu8.com/highlight/detail?id=2432692499","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2432692499?lang=zh_cn&edition=full","pubTime":"2024-05-02 10:50","pubTimestamp":1714618200,"startTime":"0","endTime":"0","summary":"[大手成交]中国生物制药(01177)在上午10:50出现大手买入,成交量为110万,成交价为港币$2.82,涉资310.2万。至目前为止,股价升4.074%,今日最高价为$2.82,而最低价为$2.72,总成交量为2.167千万股,总成交金额港币$5.979千万。","market":"fut","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180205145550051_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180205145550051_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAV2405024013/aamm-all-category","is_publish_highlight":false,"gpt_icon":0},{"id":"2431497321","title":"中国生物制药:正大天晴药业安奈克替尼获批 上市81.08%客观缓解率","url":"https://stock-news.laohu8.com/highlight/detail?id=2431497321","media":"和讯网","top":-1,"share":"https://www.laohu8.com/m/news/2431497321?lang=zh_cn&edition=full","pubTime":"2024-04-30 19:22","pubTimestamp":1714476120,"startTime":"0","endTime":"0","summary":"【港股龙头药企中国生物制药下属正大天晴药业集团1类创新药富马酸安奈克替尼胶囊获国家药监局批准上市,为国内首个用于ROS1阳性非小细胞肺癌的靶向药。】 中国生物制药宣布,其子公司正大天晴药业集团研发的富马酸安奈克替尼胶囊获得国家药品监督管理局的批准,标志着国产创新药在非小细胞肺癌治疗领域取得重大突破。据悉,肺癌是中国发病率和死亡率最高的癌症类型,非小细胞肺癌占其80%至85%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024043021543887c40d3e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024043021543887c40d3e&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431393459","title":"【港股通】中国生物制药(01177):1类创新药富马酸安奈克替尼胶囊获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2431393459","media":"金吾财讯","top":-1,"share":"https://www.laohu8.com/m/news/2431393459?lang=zh_cn&edition=full","pubTime":"2024-04-30 16:47","pubTimestamp":1714466824,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中国生物制药(01177)公布,集团自主研发的1类创新药富马酸安奈克替尼胶囊“Unecritinib (TQ-B3101)”(商品名:安柏尼)已获得中国国家药品监督管理局的上市批准,用于ROS1阳性的局部晚期或转移性非小细胞肺癌(NSCLC)成人患者的治疗。这是首个获批用于治疗ROS1阳性的局部晚期或转移性非小细胞肺癌成人患者的国产靶向药。安奈克替尼是集团自主研发的一款酪氨酸激酶ROS1/ALK/c-Met小分子抑制剂。","market":"sh","thumbnail":"https://static.szfiu.com/news/20200908/MDgxZGVmMDU5NGQxM2FkZGQzODVkYTY4OWM4NjkxNzk5NzY4NzQ2MDU0.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200908/MDgxZGVmMDU5NGQxM2FkZGQzODVkYTY4OWM4NjkxNzk5NzY4NzQ2MDU0.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1936100","is_publish_highlight":false,"gpt_icon":0},{"id":"2431393177","title":"中国生物制药(01177.HK)一款自主研究新药获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2431393177","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2431393177?lang=zh_cn&edition=full","pubTime":"2024-04-30 16:40","pubTimestamp":1714466400,"startTime":"0","endTime":"0","summary":"中国生物制药公布,其自主研发的1类创新药富马酸安奈克替尼胶囊“Unecritinib ”已获得中国国家药品监督管理局的上市批准,用于ROS1阳性的局部晚期或转移性非小细胞肺癌成人患者的治疗。安奈克替尼是公司自主研发的一款酪氨酸激酶ROS1/ALK/c-Met小分子抑制剂。公司表示,其在2022年6月基于一项研究,安奈克替尼在内地递交新药上市申请。(港股报价延迟最少十五分钟。沽空资料截至 2024-04-30 16:25。","market":"other","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20220728114525438_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20220728114525438_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/analysis/china-hot-topic-content.aspx?id=NOW.1346509&catg=4&source=AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2431398286","title":"中国生物制药(01177)自主研发的1类创新药富马酸安奈克替尼胶囊获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2431398286","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2431398286?lang=zh_cn&edition=full","pubTime":"2024-04-30 16:35","pubTimestamp":1714466146,"startTime":"0","endTime":"0","summary":"智通财经APP讯,中国生物制药 公布,该集团自主研发的1类创新药富马酸安奈克替尼胶囊“Unecritinib ”已获得中国国家药品监督管理局的上市批准,用于ROS1阳性的局部晚期或转移性非小细胞肺癌成人患者的治疗。安奈克替尼是该集团自主研发的一款酪氨酸激酶ROS1/ALK/c-Met小分子抑制剂。2022年6月,基于一项《评价TQ-B3101胶囊单药治疗ROS1阳性NSCLC受试者疗效和安全性的II期单臂、多中心临床研究》,安奈克替尼在中国递交新药上市申请。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1116211.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2431398349","title":"中国生物制药04月30日获主力加仓1955万元 环比增加649.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2431398349","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2431398349?lang=zh_cn&edition=full","pubTime":"2024-04-30 16:15","pubTimestamp":1714464935,"startTime":"0","endTime":"0","summary":"04月30日, 中国生物制药股价跌3.91%,报收2.70元,成交金额2.32亿元,换手率0.45%,振幅3.91%,量比1.33。中国生物制药今日主力资金净流入1955万元,上一交易日主力净流入261万元,今日环比增加649.04%。该股近5个交易日上涨4.26%,主力资金累计净流入10万元,其中1个交易日为股价下跌时净流入;近20日主力资金累计净流出7087万元,其中净流出天数为13日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024043016161287c2e380&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024043016161287c2e380&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431488359","title":"港股概念追踪 |ASCO研究标题发布 机构关注国产创新药产业机会(附概念股)","url":"https://stock-news.laohu8.com/highlight/detail?id=2431488359","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2431488359?lang=zh_cn&edition=full","pubTime":"2024-04-30 14:00","pubTimestamp":1714456822,"startTime":"0","endTime":"0","summary":"2024年美国临床肿瘤学会年会的研究标题于4月25日公布,纳入约5900余摘要。工银瑞信基金认为,考虑到将在二季度举办的美国临床肿瘤学会年会将有大量ADC数据读出,届时将对创新药形成催化,叠加行业本身的政策利好,长期维度来看创新药板块仍值得关注。该行看好公司作为全球实体瘤CAR-T龙头企业,其CT053、CT041等管线陆续商业化带来成长性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1116125.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2431898665","title":"中国生物制药(01177):52项研究成果将在2024年ASCO年会公布","url":"https://stock-news.laohu8.com/highlight/detail?id=2431898665","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2431898665?lang=zh_cn&edition=full","pubTime":"2024-04-29 22:56","pubTimestamp":1714402597,"startTime":"0","endTime":"0","summary":"智通财经APP讯,中国生物制药(01177)发布公告,集团1类创新药“安罗替尼(小分子多靶点受体酪氨酸激酶抑制剂)”、“艾贝格司亭α(第三代长效G-CSF)”、“派安普利单抗(抗PD-1)”及在研创新药项目“FS222(PD-L1/CD137双抗)”、“贝莫苏拜单抗(抗PDL1)”、“TQB3617(BET抑制剂)”、“TQB3728(IAP拮抗剂)”、“TQB2930(HER2双抗)”等将在2024年美国临床肿瘤学会(ASCO)年会公布52项最新研究成果,涵盖骨与软组织肉瘤、肺癌、头颈部肿瘤、消化系统肿瘤、妇科肿瘤、乳腺癌、恶性肿瘤等多个瘤种的临床研究和基础研究。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1115396.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2431869524","title":"中国生物制药:以创新填补临床空白","url":"https://stock-news.laohu8.com/highlight/detail?id=2431869524","media":"经济参考网","top":-1,"share":"https://www.laohu8.com/m/news/2431869524?lang=zh_cn&edition=full","pubTime":"2024-04-29 20:44","pubTimestamp":1714394649,"startTime":"0","endTime":"0","summary":"4月29日,中国生物制药发布2023年度可持续发展报告。报告指出,中国生物制药围绕疾病治疗需求、患者用药需求、伙伴成长需求与环境改善需求,系统推动多项ESG管理实践专项工作。在全面创新战略的核心驱动下,中国生物制药持续推动医药可及性的拓展,年度研发投入金额44.03亿元。报告期内,共有27款药品获批上市或新增适应症,持续填补临床空白。截至报告期末,中国生物制药已上市罕见病药物4个,在审在研罕见病药物项目6个。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404292125508b624998&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404292125508b624998&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430123185","title":"中国生物制药(01177.HK)创新药TQA3038完成I期临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2430123185","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2430123185?lang=zh_cn&edition=full","pubTime":"2024-04-26 00:39","pubTimestamp":1714063140,"startTime":"0","endTime":"0","summary":"中国生物制药(01177.HK) 公布,集团自主研发的1类创新药“TQA3038 (siRNA)”已于近日顺利完成I期临床研究。结果显示,TQA3038具有良好的安全性和耐受性,与其他在研同类siRNA药物的安全性相似;药代动力学特征与其非临床药代特征一致。TQA3038注射液是一种靶向乙型肝炎病毒(HBV)的小干扰RNA(siRNA)药物,适应症为慢性乙型肝炎。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-04-25 16:25。)AASTOCKS新闻","market":"us","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20220728114525438_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20220728114525438_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1345171/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2430474785","title":"中国生物制药(01177):1类创新药“TQA3038 (siRNA)”完成I期临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2430474785","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2430474785?lang=zh_cn&edition=full","pubTime":"2024-04-25 18:05","pubTimestamp":1714039536,"startTime":"0","endTime":"0","summary":"智通财经APP讯,中国生物制药 发布公告,集团自主研发的1类创新药“TQA3038 ”已于近日顺利完成I期临床研究。TQA3038采用具有自主知识产权的核酸序列,与目前临床进展最快的siRNA 相比,具有更强的体外及体内抗病毒活性。集团发起的“评价TQA3038在健康成年受试者中安全性、耐受性、药代动力学特征的随机、双盲、安慰剂对照的I期临床研究”已于近日顺利完成。集团将于近期启动TQA3038注射液在慢性乙型肝炎患者中的后续临床研究。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1110081.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2430427790","title":"中国生物制药04月25日遭主力抛售1512万元 环比增加987.77%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430427790","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2430427790?lang=zh_cn&edition=full","pubTime":"2024-04-25 16:16","pubTimestamp":1714032999,"startTime":"0","endTime":"0","summary":"04月25日, 中国生物制药股价涨2.24%,报收2.74元,成交金额2.48亿元,换手率0.48%,振幅5.60%,量比1.06。中国生物制药今日主力资金净流出1512万元,连续3日净流出,上一交易日主力净流出139万元,今日环比增加987.77%。近一年数据显示,该股主力连续3日净流出后,次日下跌概率为66.67%,平均跌幅为2.00%。该股近5个交易日上涨12.76%,主力资金累计净流出3796万元;近20日主力资金累计净流出6422万元,其中净流出天数为13日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404251617418b521d2a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404251617418b521d2a&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430589442","title":"中国生物制药(01177)出现大手卖出82.5万股,成交价$2.79,涉资230.175万","url":"https://stock-news.laohu8.com/highlight/detail?id=2430589442","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2430589442?lang=zh_cn&edition=full","pubTime":"2024-04-25 13:03","pubTimestamp":1714021380,"startTime":"0","endTime":"0","summary":"[大手成交]中国生物制药(01177)在下午01:03出现大手卖出,成交量为82.5万,成交价为港币$2.79,涉资230.175万。至目前为止,股价升4.104%,今日最高价为$2.81,而最低价为$2.66,总成交量为5.972千万股,总成交金额港币$1.646亿。","market":"other","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180416150431576_s.png","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180416150431576_s.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAV2404255042/aamm-all-category","is_publish_highlight":false,"gpt_icon":0},{"id":"2429410652","title":"中国生物制药(01177)出现大手买入140万股,成交价$2.66,涉资372.4万","url":"https://stock-news.laohu8.com/highlight/detail?id=2429410652","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2429410652?lang=zh_cn&edition=full","pubTime":"2024-04-24 13:00","pubTimestamp":1713934800,"startTime":"0","endTime":"0","summary":"[大手成交]中国生物制药(01177)在下午01:00出现大手买入,成交量为140万,成交价为港币$2.66,涉资372.4万。至目前为止,股价升3.101%,今日最高价为$2.68,而最低价为$2.58,总成交量为3.041千万股,总成交金额港币$8.021千万。","market":"fut","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180416150431576_s.png","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180416150431576_s.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAV2404243778/aamm-all-category","is_publish_highlight":false,"gpt_icon":0},{"id":"2429121280","title":"中国生物制药(01177.HK)获主席谢其润增持200万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2429121280","media":"港股那点事","top":-1,"share":"https://www.laohu8.com/m/news/2429121280?lang=zh_cn&edition=full","pubTime":"2024-04-24 07:35","pubTimestamp":1713915343,"startTime":"0","endTime":"0","summary":"格隆汇4月24日丨根据联交所最新权益披露资料显示,2024年4月23日,中国生物制药(01177.HK)获执行董事兼主席谢其润在场内以每股均价2.5891港元增持200万股,涉资约517.82万港元。增持后,谢其润最新持股数目为600万股,持股比例由0.02%上升至0.03%。\n\n股市回暖,抄底炒股先开户!智能定投、条件单、个股雷达……送给你>>\n\n\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-04-24/doc-inaswpfk8950983.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-04-24/doc-inaswpfk8950983.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429245139","title":"中国生物制药(01177)出现大手买入180万股,成交价$2.59,涉资466.2万","url":"https://stock-news.laohu8.com/highlight/detail?id=2429245139","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2429245139?lang=zh_cn&edition=full","pubTime":"2024-04-23 11:30","pubTimestamp":1713843000,"startTime":"0","endTime":"0","summary":"[大手成交]中国生物制药(01177)在上午11:30出现大手买入,成交量为180万,成交价为港币$2.59,涉资466.2万。至目前为止,股价升1.181%,今日最高价为$2.59,而最低价为$2.51,总成交量为1.741千万股,总成交金额港币$4.445千万。","market":"fut","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180126132515779_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180126132515779_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAV2404233157/aamm-all-category","is_publish_highlight":false,"gpt_icon":0},{"id":"2429613900","title":"中国生物制药(01177.HK)获执行董事谢承润增持500万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2429613900","media":"格隆汇资讯","top":-1,"share":"https://www.laohu8.com/m/news/2429613900?lang=zh_cn&edition=full","pubTime":"2024-04-23 06:48","pubTimestamp":1713826086,"startTime":"0","endTime":"0","summary":"格隆汇4月23日丨根据联交所最新权益披露资料显示,2024年4月19日,中国生物制药(01177.HK)获执行董事谢承润在场内以每股均价2.3239港元增持500万股,涉资约1161.95万港元。增持后,谢承润最新持股数目为4,055,000,000股,持股比例由21.54%上升至21.57%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404230648178b47ab61&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404230648178b47ab61&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429949756","title":"大涨近9% 中国生物制药大股东增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2429949756","media":"证券时报网","top":-1,"share":"https://www.laohu8.com/m/news/2429949756?lang=zh_cn&edition=full","pubTime":"2024-04-22 18:31","pubTimestamp":1713781860,"startTime":"0","endTime":"0","summary":"证券时报e公司讯,4月22日,港股三大指数全线收高,科技、医药股走强。中国生物制药以近9%的涨幅领涨当天生物医药股,石药集团、复星医药、信达生物分别上涨3.99%、3.32%、2.26%。当天盘后,香港联交所披露文件显示,中国生物制药第一大股东、公司CEO谢承润于4月19日以每股均价2.32港元增持中国生物制药500万股普通股股份,价值约1161.95万港元。增持后,谢承润最新持股数目为40.55亿股股份,好仓比例由21.54%升至21.57%。联交所文件还显示,4月19日,中国生物制药董事会主席谢其润也在场内以每股均价2.32港元增持250万股,涉资约580.58万港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404221832178b45c914&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404221832178b45c914&s=b","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sinobiopharm.com","stockEarnings":[{"period":"1week","weight":0.0511},{"period":"1month","weight":-0.0303},{"period":"3month","weight":0.0105},{"period":"6month","weight":-0.1403},{"period":"1year","weight":-0.3049},{"period":"ytd","weight":-0.17}],"compareEarnings":[{"period":"1week","weight":0.0534},{"period":"1month","weight":0.0753},{"period":"3month","weight":0.1721},{"period":"6month","weight":0.0307},{"period":"1year","weight":-0.0757},{"period":"ytd","weight":0.068}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"中国生物制药有限公司是一家主要从事药品业务的投资控股公司。该公司通过三个业务分部进行运营。中药现代制剂及西药分部从事生产、销售及配销中药现代制剂产品及西药产品业务。投资分部从事长期及短期投资业务。其他分部主要从事研发活动、向第三方提供服务以及从事相关医疗及医院业务。该公司还通过其子公司从事持有物业、销售健康食品、验光配镜以及零售与批发视光和听力产品业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":0.009982},{"month":2,"riseRate":0.666667,"avgChangeRate":0.059578},{"month":3,"riseRate":0.571429,"avgChangeRate":0.043859},{"month":4,"riseRate":0.47619,"avgChangeRate":0.024931},{"month":5,"riseRate":0.714286,"avgChangeRate":0.039719},{"month":6,"riseRate":0.35,"avgChangeRate":0.003696},{"month":7,"riseRate":0.6,"avgChangeRate":0.029101},{"month":8,"riseRate":0.35,"avgChangeRate":-0.023106},{"month":9,"riseRate":0.35,"avgChangeRate":-0.024746},{"month":10,"riseRate":0.6,"avgChangeRate":0.036433},{"month":11,"riseRate":0.55,"avgChangeRate":0.076694},{"month":12,"riseRate":0.45,"avgChangeRate":-0.005852}],"exchange":"SEHK","name":"中国生物制药","nameEN":"SINO BIOPHARM"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"中国生物制药(01177)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供中国生物制药(01177)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"中国生物制药,01177,中国生物制药股票,中国生物制药股票老虎,中国生物制药股票老虎国际,中国生物制药行情,中国生物制药股票行情,中国生物制药股价,中国生物制药股市,中国生物制药股票价格,中国生物制药股票交易,中国生物制药股票购买,中国生物制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"中国生物制药(01177)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供中国生物制药(01177)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}